tiprankstipranks
The Fly

Cytokinetics’ data supports aficamten’s potential, says H.C. Wainwright

Cytokinetics’ data supports aficamten’s potential, says H.C. Wainwright

Cytokinetics (CYTK) on Monday shared new analyses related to aficamten’s effects associated with standard of care combination therapy and its long-term effects on cardiac structure and function that are expected to be presented at the upcoming Annual American College of Cardiology Scientific Session & Expo 2025, H.C. Wainwright analyst Joseph Pantginis tells investors. The firm thinks the results add to previous profile-building observations supporting aficamten’s potential for cardiac remodeling. H.C. Wainwright reiterates Cytokinetics as a Top Pick and keeps a Buy rating and $120 price target on the shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com